Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) Stock: Insider Deborah Andrews Acquires 25,000 Shares

Key Points

  • Director Deborah Andrews bought 25,000 shares at an average of $0.80, investing $20,000 and increasing her direct holdings by 160.48% to 40,578 shares.
  • Lineage reported quarterly EPS of -$0.03, matching analyst estimates, but revenue of $1.43 million fell short of the $2.32 million consensus.
  • Analysts rate the stock a “Moderate Buy,” with an average price target of $6.25; shares opened at $0.82, near their 52-week low of $0.77.

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX - Get Free Report) Director Deborah Andrews bought 25,000 shares of the company's stock in a transaction that occurred on Monday, November 16th. The shares were bought at an average price of $0.80 per share, with a total value of $20,000.00. Following the completion of the acquisition, the director directly owned 40,578 shares in the company, valued at $32,462.40. This trade represents a 160.48% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Lineage Cell Therapeutics Stock Performance

LCTX opened at $0.82 on Wednesday. The stock's 50 day simple moving average is $0.99 and its 200 day simple moving average is $1.29. Lineage Cell Therapeutics, Inc. has a 1 year low of $0.77 and a 1 year high of $1.99.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX - Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($0.03) EPS for the quarter, hitting analysts' consensus estimates of ($0.03). Lineage Cell Therapeutics had a return on equity of 3.16% and a net margin of 16.18%. The business had revenue of $1.43 million for the quarter, compared to analysts' expectations of $2.32 million. Analysts expect that Lineage Cell Therapeutics, Inc. will post -0.04 EPS for the current fiscal year.

Analysts Set New Price Targets




Separately, Raymond James Financial restated a "market perform" rating on shares of Lineage Cell Therapeutics in a report on Friday. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $6.25.

Check Out Our Latest Research Report on LCTX

Hedge Funds Weigh In On Lineage Cell Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. StoneX Group Inc. boosted its holdings in shares of Lineage Cell Therapeutics by 74.9% during the third quarter. StoneX Group Inc. now owns 29,747 shares of the company's stock worth $30,000 after purchasing an additional 12,739 shares during the period. Equitable Holdings Inc. purchased a new position in Lineage Cell Therapeutics during the 2nd quarter valued at about $39,000. Two Sigma Securities LLC increased its holdings in Lineage Cell Therapeutics by 85.4% during the 2nd quarter. Two Sigma Securities LLC now owns 37,793 shares of the company's stock valued at $50,000 after purchasing an additional 17,403 shares during the period. State of Wyoming bought a new position in Lineage Cell Therapeutics during the 2nd quarter valued at approximately $57,000. Finally, Cibc World Market Inc. bought a new position in Lineage Cell Therapeutics during the 2nd quarter valued at approximately $62,000. 62.47% of the stock is owned by institutional investors.

Lineage Cell Therapeutics Company Profile

(Get Free Report)

Lineage Cell Therapeutics is a biotechnology company developing cell-based therapies for serious medical conditions. The company uses its cell therapy platform to create and manufacture specialized human cells intended to replace or support damaged cells and tissues. Its programs include OpRegen, a retinal pigment epithelial cell therapy being developed for retinal diseases; OPC1, an oligodendrocyte progenitor cell therapy for spinal cord injury; ANP1, an auditory neuron progenitor cell program for hearing loss; and VAC2, a cell-based cancer immunotherapy.

See Also

This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].

Insider Buying or Selling at Lineage Cell Therapeutics?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Lineage Cell Therapeutics and related companies.
Free Insider Buying and Selling Newsletter
Enter your email address below to receive InsiderTrades.com's daily insider buying and selling report.
From Our Partners

Most Read This Month

Recent Articles